NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Myriad Genetics' BRACAnalysis CDx as a complementary diagnostic to identify ovarian cancer patients with germline BRCA mutations who are likely to benefit most from treatment with Zejula (niraparib).
Menu
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Jul
23
Sponsored by
Qiagen
What's Popular?
In Molecular Diagnostics